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ABSTRACT
Objective: To analyze the aberrant expression of the GIPR and LHCGR in different forms of 
adrenocortical hyperplasia: ACTH-independent macronodular adrenal hyperplasia (AIMAH), 
primary pigmented nodular adrenocortical disease (PPNAD) and diffuse adrenal hyperplasia 
secondary to Cushing’s disease (DAHCD). Methods: We quantified GIPR and LHCGR expres-
sions using real time PCR in 20 patients with adrenocortical hyperplasia (seven with AIMAH, 
five with PPNAD, and eight with DAHCD). Normal adrenals tissues were used as control and 
the relative expression was compared with β-actin. Results: GIPR and LHCGR expressions 
were demonstrated in all tissues studied. Median GIPR and LHCGR mRNA levels were 1.6; 
0.4; 0.5 and 1.3; 0.9; 1.0 in adrenocortical tissues from AIMAH, PPNAD and DAHCD respecti-
vely. There were no differences between GIPR and LHCGR expressions in all tissues studied. 
Conclusions: GIPR and LHCGR overexpression were not identified in the studied cases, thus 
suggesting that this molecular mechanism is not involved in adrenocortical hyperplasia in 
our patients. Arq Bras Endocrinol Metab. 2009;53(3):326-31.
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RESUMO
Objetivo: Analisar a expressão aberrante do GIPR e do LHCGR em diferentes formas de 
hiperplasias adrenocorticais: hiperplasia adrenal macronodular independente de ACTH 
(AIMAH), doença adrenocortical nodular pigmentada primária (PPNAD) e hiperplasia adre-
nal difusa secundária à doença de Cushing (DAHCD). Métodos: Quantificou-se por PCR em 
tempo real a expressão desses receptores em 20 pacientes: sete com AIMAH, cinco com 
PPNAD e oito com DAHCD. Adrenais normais foram utilizadas como controle e a expressão 
relativa desses receptores foi comparada à expressão da β-actina. Resultados: A expressão 
desses receptores foi demonstrada em todos os tecidos estudados. A mediana da expres-
são do GIPR e do LHCGR foi de 1,6; 0,4; 0,5 e de 1,3; 0,9; 1,0 nos tecidos dos pacientes com 
AIMAH, PPNAD e DAHCD, respectivamente. Não houve diferença significativa na expressão 
desses receptores nos tecidos estudados. Conclusões: Hiperexpressão do GIPR e do LHCGR 
não foi observada, sugerindo que esse mecanismo não está envolvido na patogênese mole-
cular da hiperplasia adrenal nesses pacientes. Arq Bras Endocrinol Metab. 2009;53(3):326-31.
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INTRODUCTION
ACTH-independent Cushing’s syndrome may oc-cur due to adrenocortical tumors and different 
kinds of hyper plasia: ACTH-independent macronodu-
lar adrenal hyperplasia (AIMAH), primary pigmented 
nodular adrenocortical disease (PPNAD) and its vari-
ant subtype, non-pigmented micronodular hyperpla-
sia (1-3).
The pathways involved in ACTH-independent hor-
mone secretion and cell proliferation in these disor-
ders have not been completely elucidated (4-6). The 
cortisol production in AIMAH has been shown to be 
regulated by eutopic and ectopic aberrant expression of 
G-protein coupled receptors (1,2,7-9). 
In PPNAD, presented frequently as part of Carney com-
plex syndrome (10), germline mutations of PRKAR1A 
and, recently, PDE11A mutations were related to the 
etiology of the disease (11,12).
The aberrant expression of G-protein coupled 
receptor has been related to some cases of adrenal 
hyperplasia. The glucose-dependent insulinotropic 
peptide receptor (GIPR), a member of the secretin-
vasoactive intestinal peptide receptor family, is widely 
distributed in peripheral organs as well as in the brain 
(13). During the last decade, GIPR overexpression 
has been identified in the adrenals of patients with 
Cushing’s syndrome due to AIMAH and adrenal 
adenoma (2,14-18). Its expression has also been de-
scribed in adrenal hyperplasia secondary to Cushing’s 
disease, however, the form how GIPR overexpression 
stimulates the steroidogenesis pathway remains un-
certain (19,20).
The luteinizing hormone receptor (LHCGR), a 
G protein-coupled receptor mainly involved in the 
regulation of gonadal functions (21), is normally ex-
pressed in the human zona reticularis of the adrenal 
gland (22). The aberrant LHCGR adrenal expression 
was first identified in a French-Canadian woman with 
transient Cushing’s syndrome during pregnancies that 
reappeared after post-menopausal LH increase (23). 
Overexpression of this receptor was then identified in 
several in vitro studies of steroid-secreting AIMAH and 
adrenocortical tumors (24-26).
The aim of this study is to investigate, by using real 
time PCR, if the aberrant expression of these receptors, 
GIPR and LHCGR, would be involved in adrenal en-
largement in PPNAD and Cushing’s disease, as well as 
in our cases of AIMAH.
METHODS
The study was approved by the Ethical Committee of 
Hospital das Clínicas, São Paulo, Brazil, and written 
informed consent was obtained from all patients. We 
studied 20 Brazilian patients with adrenocortical dis-
orders (18 females and 2 males; age ranged from 18 to 
69 years old). Seven patients had AIMAH, five had PP-
NAD and eight patients had Cushing’s disease. Com-
plete clinical and molecular features of these patients 
are shown in table 1. The pre-surgical hormonal evalu-
ation of the patients included peripheral blood determi-
nation of electrolytes, LH, FSH, testosterone, estradi-
ol, ACTH, dehydroepiandrosterone sulfate (DHEAS), 
dehydroepiandrosterone (DHEA), androstenedione, 
11-deoxycortisol, aldosterone, plasmatic renin activity, 
cortisol levels in basal condition and after overnight ad-
ministration of 1 and 8 mg of dexamethasone. Urinary 
cortisol of 24 hours was also determined.
Six of seven cases of AIMAH (patients 2-7, Table 1) 
were previously submitted to an in vivo screening pro-
tocol for the aberrant receptor presence (27) and two 
siblings (cases 5 and 7) have presented a cortisol incre-
ment > 50% after cisapride test, suggesting an abnormal 
response due to 5-HT4 receptor. 
Quantitative expression of GIPR and LHCGR
All patients underwent bilateral or unilateral adrenalec-
tomy, except for two patients (cases 5 and 6 of Table 1), 
in whom adrenal biopsies were performed. Adrenal tis-
sue was obtained after surgical proceedings. Tumor sam-
ples were obtained from the core of the excised tumors 
to minimize possible contamination by the surrounding 
normal tissue. Necrotic and hemorrhagic areas were 
also avoided. Nodule tissue fragments were immediately 
stored in liquid nitrogen until RNA extraction.
RNA extraction, DNA synthesis and RT-PCR
Total RNA was isolated from frozen tissue using Trizol 
Reagent (Invitrogen, Grand Island, NY, USA). Reverse 
transcription (RT) was performed in 5 µg of total RNA 
of each sample using Multiscribe from a High-capacity 
cDNA Archive Kit (Applied Biosystems, Foster City, 
CA, USA) in a 50 µL total reaction. 
Quantitative real time PCR was carried out in the 
Applied Biosystems 7000 real-time PCR System. Taq-
Man Gene Expression Assays (Applied Biosystems, Fos-
ter City, CA, USA) were especially designed to amplify 
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Table 1. Clinical and molecular data of 20 patients with adrenocortical hyperplasia
Patients Age(years) Sex Phenotype Genetic alterations Diagnosis
GIPR
*Expression
LHCGR
*Expression
1 34 F Cushing’s syndrome - AIMAH 138.5 0.9
2 53 F Cushing’s syndrome  - AIMAH 13 1.3
3 26 F Cushing’s syndrome  - AIMAH 1.6 3.0
4 69 F Cushing’s syndrome  - AIMAH 0.8 1.3
5 51 F Cushing’s syndrome  - AIMAH 0.6 0.8
6 45 F Cushing’s syndrome  - AIMAH 3.0 2.1
7 44 M Cushing’s syndrome  - AIMAH 0.2 0.05
8 18 M Cushing’s syndrome Y21X(PRKAR1A) PPNAD 0.2 0.9
9 55 F Cushing’s syndrome  - PPNAD 0.05 0.4
10 29 F Cushing’s syndrome  - PPNAD 0.4 0.9
11 35 F Cushing’s syndrome  - PPNAD 0.5 1.8
12 23 F Cushing’s syndrome  - PPNAD 0.4 2.1
13 31 F Cushing’s syndrome DAHCD 0.3 0.5
14 34 F Cushing’s syndrome DAHCD 0.9 0.7
15 35 F Cushing’s syndrome DAHCD 0.7 0.7
16 32 F Cushing’s syndrome DAHCD 0.5 0.8
17 31 F Cushing’s syndrome DAHCD 0.2 1.1
18 27 F Cushing’s syndrome DAHCD 1.5 1.3
19 33 F Cushing’s syndrome DAHCD 0.3 1.4
20 32 F Cushing’s syndrome DAHCD 0.4 1.7
Normal adrenal 0.9 1.3
Normal adrenal 0.9 1.5
Normal adrenal 0.9 1.8
Normal adrenal 0.5 1.9
Normal adrenal 1.4 3.0
Normal adrenal 0.4 3.4
Normal adrenal 0.1 3.7
Normal adrenal 0.5 9.6
Control tissue 
(pancreas) 74.4
Control tissue (testes)    45.3
F: female; M: male; DAHCD: diffuse adrenal hyperplasia secondary to Cushing disease.
* Relative expression levels compared to β-actin.
the LHCGR. The GIPR amplification was performed 
using available commercial primers and a probe (Assay 
ID Hs006092_m1, Applied Biosystems Foster City, CA, 
USA). The LHCGR amplification was performed with 
the following pair of primers, 5’ GCACAATGGAGC-
CTTCCGT 3’; 5’ GGCCTGCAATTTGGTGGAA 3’ 
and the probe 5’ CCGAAAACCTTGGATATTT 3’. 
β-actin (assay ID-4326315E, Applied Biosystems Foster 
City, CA, USA) was chosen as the internal control. Mul-
tiplex reactions consisted of 12.5 µL 2x TaqMan Uni-
versal PCR master mix, 1.25 µL of each 20x assay on 
demand, 1.5 µL of cDNA and water to complete 25 µL 
final volume. PCR parameters were 50˚C for two min-
utes, 95˚C for ten minutes followed by 50 cycles at 95˚C 
for 15 seconds and 60˚C for 1 minute. 
Validation experiments were performed to verify 
that the amplification efficiency of the controls was 
similar to that of the target genes. 
A cycle threshold (CT) value in the linear range of 
amplification was selected for each sample in triplicate 
and normalized to β-actin expression levels. The rela-
tive expression levels were analyzed using the 2-ΔΔCT 
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where the ΔΔCT is the difference between the selected 
ΔCT value of a particular sample and the ΔCT of a pool 
using 61 normal adrenals from autopsies (Clontech, 
Palo Alto, CA, USA) (28). The mean expression of 
the target genes in the normal adrenals pool was as-
signed an expression value of 1.0 and the fold increase 
or decrease in the expression levels in each hyperplasia 
sample was determined by comparison.Pancreas and 
testis were obtained during the surgical resections of 
kidney tumors, pancreatic cysts and gonads, being used 
as positive expression controls for GIPR and LHCGR, 
respectively.
Statistical analysis
GIPR and LHCGR expressions from all tissues ana-
lyzed were compared by Kruskal Wallis test. The value 
of p < 0.05 was considered statistically significant. In 
each group of patients, data are presented as median 
and range. The Spearman test was used to establish 
correlation between the receptor expression, clinical 
aspects and hormonal levels of patients.
RESULTS
The expression of GIPR and LHCGR was demon-
strated in all tissues studied. GIPR expression was very 
low in all normal adrenal tissues studied (median level: 
0.7, ranging from 0.1 to 1.4) while LHCGR expres-
sion levels in normal adrenal tissues were more vari-
able (median level: 2.5, ranging from 1.3 to 9.6). 
Median GIPR mRNA levels were 1.6, 0.4 and 0.5 in 
adrenocortical tissues from patients with AIMAH, 
PPNAD and Cushing’s disease respectively (Figure 
1). Median LHCGR mRNA levels were 1.3, 0.9 
and 1.0 in adrenocortical tissue from patients with 
AIMAH, PPNAD and Cushing’s disease respectively 
(Figure 2). The median and ranges of both receptor 
expressions are shown in table 2.
No significant difference in GIPR expression was 
observed among these forms of adrenocortical hy-
perplasia and normal adrenals, while it was observed 
that the LHCGR expression was lower in AIMAH 
(p = 0.02) and Cushing’s disease (p = 0.02), but not 
statistically significant in PPNAD when compared to 
normal adrenals (p = 0.06). We did not observe any 
statistical difference between GIPR and LHCGR 
expressions in the different forms of hyperplasia stu-
died (Table 2).
Figure 1. Expression levels of GIPR mRNA of 20 adrenal hyperplasia cases: five 
PPNAD, eight hyperplasia cases secondary to CD (Cushing’s disease) and seven 
AIMAH compared to eight normal adrenals.
Figure 2. Expression levels of LHCGR mRNA of 20 adrenal hyperplasia cases: five 
PPNAD, eight hyperplasia cases secondary to CD (Cushing’s disease) and seven 
AIMAH, compared to eight normal adrenals.
Table 2. GIPR and LHCGR relative expression levels (median and range) in 
adrenocortical hyperplasia
 GIPR Expression
LHCGR
Expression
AIMAH 1.6 
 (0.2 - 138.5) 
1.3 
 (0.05 - 3.0) 
PPNAD 0.4
 (0.05 - 0.5) 
0.9
 (0.4 - 2.1) 
DAHCD 0.5
 (0.2 - 1.5) 
1.0
 (0.5 - 1.7) 
Normal adrenal 0.7
 (0.1 - 1.4) 
2.5
 (1.3 - 9.6) 
DAHCD: diffuse adrenal hyperplasia secondary to Cushing’s disease.
We did not find a correlation between GIPR and 
LHCGR expression levels in adrenocortical tissues 
and pre-surgical hormonal levels (p > 0.05).
DISCUSSION
Cushing’s syndrome secondary to aberrant hormone re-
ceptors has been described by several authors in the last 
decade (7,29). This condition has been largely identified 
in AIMAH and adenomas, and some sporadic cases of 
hyperplasia secondary to Cushing’s disease and PPNAD 
were also related to this mechanism (2,8,19). Recently, 
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new patterns of LHCGR and GIPR expressions have been 
described, implicating both receptors in the pathophysi-
ology of aldosterone-secreting tumors and androgen se-
cretion resulting in hirsutism, suggesting a larger role of 
G-protein receptors in adrenocortical disease (26,30).
To investigate the potential role of GIPR and LH-
CGR expression in adrenocortical hyperplasia we stud-
ied a group of patients (20 cases) with adrenal enlarge-
ment due to several etiologies. 
Despite the molecular mechanism responsible for 
the aberrant expression of these receptors, they still 
need to be clarified (2,31-34); experimental studies 
have demonstrated that abnormal expression of GIPR 
and LHCGR in adrenocortical cells provoke phenotyp-
ic changes in these cells, leading to the deregulation in 
their proliferation fate and eliciting adrenocortical tum-
origenesis. This hyperproliferative adrenocortical tissue 
lead to GIP or LH-dependent secretion of cortisol and 
low ACTH levels (35,36). 
The abnormal adrenal expression of the functional 
LHCGR has been identified in some cases of AIMAH 
and adrenocortical tumors (23-25,37); this receptor ex-
pression has been documented in normal adrenal gland 
(38), although it was not well investigated in other 
forms of adrenocortical hyperplasia; We therefore ex-
amine the LHCGR expression in eight cases of adreno-
cortical hyperplasia secondary to Cushing’s disease and 
five cases of PPNAD that have presented lower LHCGR 
expression when compared to normal adrenal tissues. 
Our results do not support the role of this receptor in 
the adrenal enlargement due to such disorders.
The hypothesis that chronic stimulation or activa-
tion of the ACTH signaling pathway may be associated 
to GIPR expression suggested by the results of Swords 
and cols. (19) in all five patients with diffuse adrenocor-
tical hyperplasia secondary to Cushing’s disease and one 
case with PPNAD has not been confirmed (20,39). In 
our study, no difference in GIPR expression was ob-
served in the different forms of adrenocortical hyper-
plasia studied: adrenal hyperplasia secondary to Cush-
ing’s disease; AIMAH and PPNAD, as well as between 
adrenocortical hyperplasia and normal adrenals, 
which did not confirm the previously described find-
ings. However, the patient 1 showed a high expression 
level (138.5) bringing into evidence the great variability 
of GIPR expression in the adrenal hyperplasia (40,41).
In conclusion, we ruled out GIPR and LHCGR 
overexpression as being related to adrenocortical hy-
perplasia due to AIMAH and PPNAD in our cases. Our 
results suggest that GIPR is not involved in the mo-
lecular mechanisms implicated in the development of 
diffuse adrenocortical hyperplasia of Cushing’s disease. 
These data support the idea that the role of ACTH 
stimulation in the regulation of GIPR ectopic expres-
sion might be really reduced.
Acknowledgements: the authors thank to the staff of Laboratório 
de Hormônios e Genética Molecular LIM/42, and particularly, 
Emilia Modolo Pinto and Maria Aparecida Medeiros for providing 
excellent technical support. We also thank Doctor Alexander Au-
gusto Jorge and Doctor Silvia Correa Souza Leão for the statistical 
analysis. This research was supported in part by Fundação de Ampa-
ro a Pesquisa do Estado de São Paulo (Fapesp Grants 03/07449-1 
to M.H.S.C and 04/15046-7 to B.B.M.) and by Conselho Nacio-
nal de Desenvolvimento Científico e Tecnológico (CNPq Grants 
300828/2005-5 to B.B.M. and 300469/2005-5 to A.C.L.). 
Disclosure: there is no conflict of interest between the authors 
and the funding agencies that would prejudice the impartiality 
of this work.
REFERENCES
Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal 1. 
hormone receptors in adrenal Cushing’s syndrome. Endocr Rev. 
2001;22(1):75-110.
Lacroix A, Baldacchino V, Bourdeau I, Hamet P, Tremblay J. 2. 
Cushing’s syndrome variants secondary to aberrant hormone re-
ceptors. Trends Endocrinol Metab. 2004;15(8):375-82.
Stratakis CA, Boikos SA. Genetics of adrenal tumors associa-3. 
ted with Cushing’s syndrome: a new classification for bilateral 
adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab. 
2007;3(11):748-57.
Bourdeau I, D’Amour P, Hamet P, Boutin JM, Lacroix A. Aberrant 4. 
membrane hormone receptors in incidentally discovered bilate-
ral macronodular adrenal hyperplasia with subclinical Cushing’s 
syndrome. J Clin Endocrinol Metab. 2001;86(11):5534-40.
Bourdeau I, Antonini SR, Lacroix A, Kirschner LS, Matyakhina 5. 
L, Lorang D, et al. Gene array analysis of macronodular adre-
nal hyperplasia confirms clinical heterogeneity and identifies 
several candidate genes as molecular mediators. Oncogene. 
2004;23(8):1575-85.
Bourdeau I, Matyakhina L, Stergiopoulos SG, Sandrini F, Boikos 6. 
S, Stratakis CA. 17q22-24 chromosomal losses and alterations of 
protein kinase a subunit expression and activity in adrenocorti-
cotropin-independent macronodular adrenal hyperplasia. J Clin 
Endocrinol Metab. 2006;91(9):3626-32.
Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Grous-7. 
sin L, et al. In vivo and in vitro screening for illegitimate recep-
tors in adrenocorticotropin-independent macronodular adrenal 
hyperplasia causing Cushing’s syndrome: identification of two 
cases of gonadotropin/gastric inhibitory polypeptide-dependent 
hypercortisolism. J Clin Endocrinol Metab. 2005;90(3):1302-10.
Costa MH, Lacroix A. Cushing’s syndrome secondary to ACTH-8. 
independent macronodular adrenal hyperplasia. Arq Bras Endo-
crinol Metabol. 2007;51(8):1226-37.
Bourdeau I, Lampron A, Costa MH, Tadjine M, Lacroix A. Adre-9. 
nocorticotropic hormone-independent Cushing’s syndrome. Curr 
Opin Endocrinol Diabetes Obes. 2007;14(3):219-25.
Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular 10. 
features of the Carney complex: diagnostic criteria and recom-
GIPR and LHCGR expression in adrenocortical hyperplasia
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
331Arq Bras Endocrinol Metab. 2009;53/3
mendations for patient evaluation. J Clin Endocrinol Metab. 
2001;86(9):4041-6.
Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho 11. 
YS, et al. Mutations of the gene encoding the protein kinase A 
type I-alpha regulatory subunit in patients with the Carney com-
plex. Nat Genet. 2000;26(1):89-92.
Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, 12. 
Griffin KJ, et al. A genome-wide scan identifies mutations in the 
gene encoding phosphodiesterase 11A4 (PDE11A) in individuals 
with adrenocortical hyperplasia. Nat Genet. 2006;38(7):794-800.
Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric 13. 
inhibitory polypeptide receptor, a member of the secretin-vasoac-
tive intestinal peptide receptor family, is widely distributed in peri-
pheral organs and the brain. Endocrinology. 1993;133(6):2861-70.
Lacroix A, Bolté E, Tremblay J, Dupré J, Poitras P, Fournier H, 14. 
et al. Gastric inhibitory polypeptide-dependent cortisol hyper-
secretion--a new cause of Cushing’s syndrome. N Engl J Med. 
1992;327(14):974-80.
Herder WW, et al. Food-dependent Cushing’s syndrome resul-15. 
ting from abundant expression of gastric inhibitory polypeptide 
receptors in adrenal adenoma cells. J Clin Endocrinol Metab. 
1996;81:3168-72. 
Chabre O, Liakos P, Vivier J, Chaffanjon P, Labat-Moleur F, Martinie M, 16. 
et al. Cushing’s syndrome due to a gastric inhibitory polypeptide-de-
pendent adrenal adenoma: insights into hormonal control of adreno-
cortical tumorigenesis. J Clin Endocrinol Metab. 1998;83(9):3134-43.
Lebrethon MC, Avallet O, Reznik Y, Archambeaud F, Combes J, 17. 
Usdin TB, et al. Food-dependent Cushing’s syndrome: characte-
rization and functional role of gastric inhibitory polypeptide re-
ceptor in the adrenals of three patients. J Clin Endocrinol Metab. 
1998;83(12):4514-9.
N’Diaye N, Hamet P, Tremblay J, Boutin JM, Gaboury L, Lacroix A. 18. 
Asynchronous development of bilateral nodular adrenal hyper-
plasia in gastric inhibitory polypeptide-dependent cushing’s syn-
drome. J Clin Endocrinol Metab. 1999;84(8):2616-22.
Swords FM, Aylwin S, Perry L, Arola J, Grossman AB, Monson JP, 19. 
et al. The aberrant expression of the gastric inhibitory polypepti-
de (GIP) receptor in adrenal hyperplasia: does chronic adrenocor-
ticotropin exposure stimulate up-regulation of GIP receptors in 
Cushing’s disease? J Clin Endocrinol Metab. 2005;90(5):3009-16.
Antonini SR, Baldacchino V, Tremblay J, Hamet P, Lacroix A. Ex-20. 
pression of ACTH receptor pathway genes in glucose-dependent 
insulinotrophic peptide (GIP)-dependent Cushing’s syndrome. 
Clin Endocrinol (Oxf). 2006;64:29-36.
Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin 21. 
receptor, a 2002 perspective. Endocr Rev. 2002;23(2):141-74.
Abdallah MA, Lei ZM, Li X, Greenwold N, Nakajima ST, Jauniaux 22. 
E, et al. Human fetal nongonadal tissues contain human chorionic 
gonadotropin/luteinizing hormone receptors. J Clin Endocrinol 
Metab. 2004;89(2):952-6.
Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in 23. 
luteinizing hormone--dependent Cushing’s syndrome. N Engl J 
Med. 1999;341(21):1577-81.
Feelders RA, Lamberts SW24. , Hofland LJ, van Koetsveld PM, Verho-
ef-Post M, Themmen AP, et al. Luteinizing hormone (LH)-res-
ponsive Cushing’s syndrome: the demonstration of LH receptor 
messenger ribonucleic acid in hyperplastic adrenal cells, which 
respond to chorionic gonadotropin and serotonin agonists in vi-
tro. J Clin Endocrinol Metab. 2003;88(1):230-7.
Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV, et 25. 
al. Virilization in bilateral macronodular adrenal hyperplasia 
controlled by luteinizing hormone. J Clin Endocrinol Metab. 
2003;88(1):73-7.
Saner-Amigh K, Mayhew BA, Mantero F, Schiavi F, White PC, Rao 26. 
CV, et al. Elevated expression of luteinizing hormone receptor 
in aldosterone-producing adenomas. J Clin Endocrinol Metab. 
2006;91(3):1136-42.
Lacroix AM, H. Hammet, P. Clinical evaluation of the presence of 27. 
abnormal hormone receptors in adrenal Cushing’s syndrome. 
The Endocrinologist. 1999;(9):9-15. 
Livak KJ, Schmittgen TD. Analysis of relative gene expression 28. 
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) 
Method. Methods. 2001;25(4):402-8.
Mircescu H, Jilwan J, N’Diaye N, Bourdeau I, Tremblay J, Hamet 29. 
P, et al. Are ectopic or abnormal membrane hormone receptors 
frequently present in adrenal Cushing’s syndrome? J Clin Endo-
crinol Metab. 2000;85(10):3531-6.
Tsagarakis S, Tsigos C, Vassiliou V, Tsiotra P, Pratsinis H, Kletsas D, 30. 
et al. Food-dependent androgen and cortisol secretion by a gastric 
inhibitory polypeptide-receptor expressive adrenocortical adenoma 
leading to hirsutism and subclinical Cushing’s syndrome: in vivo 
and in vitro studies. J Clin Endocrinol Metab. 2001;86(2):583-9.
Antonini SR, N’Diaye N, Hamet P, Tremblay J, Lacroix A. Analy-31. 
sis of the putative promoter region of the GIP receptor gene 
(GIPR) in GIP-dependent Cushing’s syndrome (CS). Endocr Res. 
2002;28(4):755-6.
Antonini SR, N’Diaye N, Baldacchino V, Hamet P, Tremblay J, La-32. 
croix A. Analysis of the putative regulatory region of the gastric 
inhibitory polypeptide receptor gene in food-dependent Cushing’s 
syndrome. J Steroid Biochem Mol Biol. 2004;91(3):171-7.
Baldacchino V, Oble S, Décarie PO, Bourdeau I, Hamet P, Tremblay 33. 
J, et al. The Sp transcription factors are involved in the cellular ex-
pression of the human glucose-dependent insulinotropic polypep-
tide receptor gene and overexpressed in adrenals of patients with 
Cushing’s syndrome. J Mol Endocrinol. 2005;35(1):61-71.
Lampron A, Bourdeau I, Hamet P, Tremblay J, Lacroix A. Whole 34. 
genome expression profiling of glucose-dependent insulinotro-
pic peptide (GIP)- and adrenocorticotropin-dependent adrenal 
hyperplasias reveals novel targets for the study of GIP-dependent 
Cushing’s syndrome. J Clin Endocrinol Metab. 2006;91(9):3611-8.
Mazzuco TL, Chabre O, Feige JJ, Thomas M. Aberrant expression 35. 
of human luteinizing hormone receptor by adrenocortical cells is 
sufficient to provoke both hyperplasia and Cushing’s syndrome 
features. J Clin Endocrinol Metab. 2006;91(1):196-203.
Mazzuco TL, Chabre O, Sturm N, Feige JJ, Thomas M. Ectopic ex-36. 
pression of the gastric inhibitory polypeptide receptor gene is a 
sufficient genetic event to induce benign adrenocortical tumor in 
a xenotransplantation model. Endocrinology. 2006;147(2):782-90.
Wy LA, Carlson HE, Kane P, Li X, Lei ZM, Rao CV. Pregnancy-asso-37. 
ciated Cushing’s syndrome secondary to a luteinizing hormone/
human chorionic gonadotropin receptor-positive adrenal carcino-
ma. Gynecol Endocrinol. 2002;16(5):413-7.
Pabon JE, Li X, Lei ZM, Sanfilippo JS, Yussman MA, Rao CV. 38. 
Novel presence of luteinizing hormone/chorionic gonadotropin 
receptors in human adrenal glands. J Clin Endocrinol Metab. 
1996;81(6):2397-400.
N’Diaye N, Tremblay J, Hamet P, De Herder WW, Lacroix A. Adre-39. 
nocortical overexpression of gastric inhibitory polypeptide recep-
tor underlies food-dependent Cushing’s syndrome. J Clin Endo-
crinol Metab. 1998;83(8):2781-5.
Croughs RJ, Zelissen PM, van Vroonhoven TJ, Hofland LJ, N’Diaye 40. 
N, Lacroix A, et al. GIP-dependent adrenal Cushing’s syndrome 
with incomplete suppression of ACTH. Clin Endocrinol (Oxf). 
2000;52(2):235-40.
Groussin L, Perlemoine K, Contesse V, Lefebvre H, Tabarin A, 41. 
Thieblot P, et al. The ectopic expression of the gastric inhibitory 
polypeptide receptor is frequent in adrenocorticotropin-indepen-
dent bilateral macronodular adrenal hyperplasia, but rare in uni-
lateral tumors. J Clin Endocrinol Metab. 2002;87(5):1980-5.
 and LHCGR expression in adrenocortical hyperplasia
